In conclusion, the patient's quality of life was significantly improved, depression and anxiety were reduced, the patient's CD3+, CD4+, and CD4+/CD8+ indicators after treatment were higher than before treatment, and the patient's WBC, Hb, and PLT counts after treatment were lower than before treatment. The gene discussed is GSTM1; the disease is major depressive disorder.